Study On Mesoporous Molecular Sieve MCM-41 As Sustained-release Carrier Of Drugs

Mesoporous materials are characterized by large surface area and pore volume,uniform pore structure,and good biocompatibility.Because of their modifiable properties,mesoporous materials are often used as sustained drug release carriers.Mesoporous molecular sieve MCM-41 is a typical representative of mesoporous material M41S series.It has multi-level ordered structure,large specific surface area,highly ordered pore size and hexagonal pore structure,and is invariable at high temperature.At the same time,due to its surface functional groups can be modified,the drug load and drug release rate can be adjusted.And then achieve the purpose of slow release and controlled release.In this study,mesoporous molecular sieve MCM-41 was prepared by hydrothermal synthesis,and the mesoporous molecular sieve MCM-41 was modified by 1,3,5-tritylene to enlarge its pore size.Using liquid phase transplantation method,ibuprofen and tamoxifen citrate were implanted into the pores of two kinds of molecular sieve respectively.The prepared materials were characterized and analyzed by X-ray diffraction,FT-IR,SEM,TEM and N₂ adsorption-desorption,and the release of the two assembled drugs in simulated body fluids was monitored,and the following conclusions were drawn:（1）Through the drug assembly MCM-41@ibuprofen（MB）and the release of Mc M-41@ibuprofen（MMB）in simulated body fluids after reaming,it was found that:The drug assembly MB and MMB released 20.75%and 18.26%of IBU in the system within 3 h and 2 h,respectively.At 7 h and 8 h,the cumulative drug release of MB and MMB was 50.83%and 59.86%,respectively.At 40 h,the cumulative release of MB and MMB reached 96.93%and 98.06%,respectively.The inhibition performance of the two slow-release solutions of MB and MMB at different time was lower than that of IBU,but the inhibitory effect was significantly enhanced with the increase of slow-release time.Under the same conditions,the antibacterial zone diameter of MMB was larger than that of MB.Two kinds of MCM-41 molecular sieves were incubated with L929 and Bend cells respectively,and the survival rate of cells did not change significantly 72 h ago,which proved that the two kinds of MCM-41 molecular sieves had good biocompatibility.The two assembled drugs MB and MMB significantly reduced the proliferation of human breast cancer MCF-7 cells with increasing release time.It is further proved that the prepared assemblages MB and MMB have good slow release properties.（2）The drug assembly MCM-41@Tamoxifen citrate（MT）and reamer MCM-41@Tamoxifen citrate（MMT）were released in simulated body fluids.The release rates of MT and MMT were 78.66%and 86.33%in the first 8 h,respectively.After 8 h,the release rate of MMT and MT gradually leveled off.The assembled MMT and MT released 99.9%and 94.5%of the loaded drugs at 32h and 48h,respectively.The effects of the two assembled drugs MT and MMT on the proliferation of human breast cancer MCF-7 cells in vitro were monitored at the cell level of the two assembled drugs MT and MMT.With the increase of the sustained release time of the drugs,the proliferation of MCF-7 cells in vitro was significantly inhibited,which proved that the two assembled drugs MT and MMT had better sustained release effects.